Table 1.

Demographic characteristics of the investigated patients

	Control (n = 10)	Levosimendan (n = 10)	P
Age, years	61 [24–69]	51 [36–62]	0.469
Males (n)	9	8	0.535
SAPS II	51 [48–68]	57 [44–68]	0.305
Comorbidities (n)
Diabetes mellitus	4	3	0.861
Dyslipidemia	3	1	0.475
Hypertension	5	3	0.563
Sepsis sites (n)
Pulmonary	5	4
Abdominal	2	1
Central venous catheter	1	1	0.562
Endocarditis	1	1
More than two sites	1	3
Mortality (%)	50	30	0.608

Data are presented as median [25th; 75th percentile] or percentage.

SAPS II indicates simplified acute physiology score.